GlassScriptPhysician profile
Leon M Rubenfaer
NPI 1487632345
$5,391.86
in general payments reported to CMS, 2019-2025
19 companies · $612 in 2025
The $612 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $396 · 2021: $1,141 · 2022: $1,021 · 2023: $705 · 2024: $1,299 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,615.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,227.28 | 2020-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $750.39 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $737.15 | 2020-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $731.22 | 2019-2025 | Rexulti |
| Alkermes, INC. | $390.62 | 2021-2024 | Lybalvi |
| Abbvie INC. | $306.15 | 2022-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $280.11 | 2021-2025 | Ingrezza |
| Corium, LLC | $211.69 | 2023-2024 | Azstarys |
| Axsome Therapeutics, INC. | $173.84 | 2022-2024 | Auvelity |
| Bausch Health US, LLC | $133.58 | 2021-2023 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $98.47 | 2022-2023 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $92.85 | 2021-2022 | |
| Eisai INC. | $73.20 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $47.73 | 2020-2021 | |
| Neuronetics, INC. | $44.30 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $31.06 | 2019 | |
| Almatica Pharma LLC | $24.88 | 2021-2022 | |
| Validus Pharmaceuticals LLC | $24.33 | 2025 | Raldesy |
| Allergan, INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Rubenfaer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.